Information on the target market size is useful information for investors.
But so is having an idea of development pathway. Are we expecting a phase 1 clinical trial in the next 1-2 years? Do we look for a development partner, or simply a supply agreement with an mRNA vaccine company for trials?
Or are they getting it ready to license as a pre-clinical asset? What is there left to do? How long will that take?
Communication is severely lacking with Noxopharm. Many other biotechs have outlined upcomming milestones with or without expected timeline.
- Forums
- ASX - By Stock
- NOX
- Ann: Noxopharm Announces Novel mRNA Vaccine Enhancer
Ann: Noxopharm Announces Novel mRNA Vaccine Enhancer, page-8
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NOX (ASX) to my watchlist
(20min delay)
|
|||||
Last
11.0¢ |
Change
0.014(14.6%) |
Mkt cap ! $32.14M |
Open | High | Low | Value | Volume |
9.2¢ | 11.5¢ | 9.2¢ | $53.30K | 518.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 48681 | 10.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
11.0¢ | 74195 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 48681 | 0.100 |
1 | 7253 | 0.099 |
2 | 23340 | 0.092 |
1 | 10989 | 0.091 |
3 | 204710 | 0.090 |
Price($) | Vol. | No. |
---|---|---|
0.110 | 69808 | 3 |
0.115 | 256630 | 6 |
0.120 | 61648 | 3 |
0.125 | 447472 | 6 |
0.130 | 199760 | 1 |
Last trade - 15.45pm 23/08/2024 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online